Doulas-AC: Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community

Sponsor
University of Pittsburgh (Other)
Overall Status
Recruiting
CT.gov ID
NCT05314179
Collaborator
(none)
5
1
1
38.6
0.1

Study Details

Study Description

Brief Summary

The proposed program, "Doulas - AC" will provide Dignity, Legacy, Advocacy and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community." The goals are to: 1) provide a community-based, trained companion to journey alongside the patient with advanced cancer, 2) to help the individual explore meaning and create legacy, 3); offer support and navigation for practical needs of illness (e.g., financial assistance for food and housing, accessing and affording medications, transportation); and 4) to provide support and connection for the bereaved family/friends, including facilitating community connections for routine health screenings and access to mental health services, as needed.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: DOULA-AC 1
N/A

Detailed Description

The patient will be contacted and consent will be obtained by telephone. Once consent is obtained, the doula will be contacted with the patient information.

The doula will then contact the patient and determine how the 3 hours/week will be sent.

The doula will be trained by the study PI. The protocols for patient engagement will be taught. At the conclusion of the training, the doula that successfully work with standardized patients will be asked to work through the protocols for each clinic visit.

The options of emotional support, practical assistance, family support, and legacy building projects will be offered. The nature and type of visits will be determined by the patient and doula. A weekly plan will be implemented by the doula which may involve conversations, creating legacy projects, conversations with family and patients, and assistance with practical issues. Following completion of data collection, descriptive statistics will be utilized to evaluate % change in patient outcomes from baseline to 2 months and study completion. Implementation outcomes will be quantified.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
5 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Pre and post intervention pilot studyPre and post intervention pilot study
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community (Doulas - AC)
Actual Study Start Date :
Mar 13, 2022
Anticipated Primary Completion Date :
Jun 1, 2025
Anticipated Study Completion Date :
Jun 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: DOULA -AC

Four hours/week of Doula and Patient engagement.

Behavioral: DOULA-AC 1
Doula and Patient will decide on details of engagement. The components to be included will be: 1) emotional support, 2)practical assistance, 3) family support, and/or 4)legacy building projects as per study protocols. The nature and type of visits will be determined by the patient and doula.

Outcome Measures

Primary Outcome Measures

  1. Change in Interpersonal Support Evaluation List (ISEL) [Baseline, up to 6 months]

    The Interpersonal Support Evaluation List (ISEL) is a 40-item scale comprised of four subscales: 1.) Tangible Support; 2.) Belonging Support; 3.) Self-esteem Support; 4.) Appraisal Support. Items are rated by participants on how true or false they believe the statements are for themselves. Answers are given on a 4-point scale ranging from 0-3: definitely false (0), probably false (1), probably true (2), definitely true (3). The ISEL is scored by summing the items to create an overall score that indicates a participant's perceived level of social support. Total scores (total of all subscales) range from 0-120. Higher ISEL scores indicate greater ability to endure stressful experiences and greater perceived social support.

  2. Change in Hospital Anxiety and Depression Scale (HADS) [Baseline, up to 6 months]

    The HADS questionnaire is a self-assessment questionnaire detecting states of anxiety and depression that includes 7 items each for depression and anxiety subscales. Scoring for each item ranges from 0 - 3. Scores of 3 for a single item denotes highest anxiety or depression level. Total overall scores (total of all subscales) range from 0 - 21. A total score of 8 or more points out of a possible 21 indicates considerable symptoms of anxiety or depression.

  3. Change in Patient-Reported Outcomes Measurement Information System (PROMIS-29) Questionnaire [Baseline, up to 6 months]

    The Patient-Reported Outcomes Measurement Information System (PROMIS-29) is a short form assessment that uses a single 0-10 numeric pain rating item and seven health domains using four items each. The seven domains included Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities. It also includes plus one pain intensity question. Total raw scores range from 0 - 290. Higher PROMIS scores indicate more severe effect of pain on domain items and on quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients diagnosed with Metastatic Breast Cancer

  2. Participants must be of African American race

  3. Participants must reside in or around Pittsburgh, Pennsylvania area

Exclusion Criteria:
  1. Inability to read or understand English

Contacts and Locations

Locations

Site City State Country Postal Code
1 UPMC Hillman Cancer Center Pittsburgh Pennsylvania United States 15232

Sponsors and Collaborators

  • University of Pittsburgh

Investigators

  • Principal Investigator: Margaret Quinn Rosenzweig, PhD, UPMC Hillman Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Margaret Quinn Rosenzweig, Professor, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT05314179
Other Study ID Numbers:
  • HCC 21-265
First Posted:
Apr 6, 2022
Last Update Posted:
Aug 12, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Margaret Quinn Rosenzweig, Professor, University of Pittsburgh
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 12, 2022